Matching articles for "Mifegymiso"
In Brief: Alternatives to Mifepristone for Medication Abortion
The Medical Letter on Drugs and Therapeutics • June 26, 2023; (Issue 1679)
The possibility that use of mifepristone (Mifeprex,
and generics) may be restricted has led to questions
about alternatives for medication...
The possibility that use of mifepristone (Mifeprex,
and generics) may be restricted has led to questions
about alternatives for medication abortion.
In Brief: Expanded Access to Mifepristone
The Medical Letter on Drugs and Therapeutics • February 20, 2023; (Issue 1670)
First approved in 2000 for termination of pregnancies
of ≤49 days' gestation, the indication for the oral
antiprogestin mifepristone (Mifeprex, and generics)
was expanded in 2016 to include pregnancies...
First approved in 2000 for termination of pregnancies
of ≤49 days' gestation, the indication for the oral
antiprogestin mifepristone (Mifeprex, and generics)
was expanded in 2016 to include pregnancies of
up to 10 weeks' gestation. A single 200-mg oral
dose of mifepristone followed 24-48 hours later by
a single 800-mcg buccal dose of the prostaglandin
analog misoprostol terminates early intrauterine
pregnancies in about 95% of women.
In Brief: Mifepristone by Mail for Pregnancy Termination
The Medical Letter on Drugs and Therapeutics • January 24, 2022; (Issue 1642)
The FDA has removed the requirement that
mifepristone (Mifeprex, and generics), a progestin
receptor antagonist approved for use in a regimen with
the prostaglandin E1 analog misoprostol (Cytotec,
and...
The FDA has removed the requirement that
mifepristone (Mifeprex, and generics), a progestin
receptor antagonist approved for use in a regimen with
the prostaglandin E1 analog misoprostol (Cytotec,
and generics) for medical termination of pregnancy,
must be dispensed in person to the patient.
Osilodrostat (Isturisa) for Cushing's Disease
The Medical Letter on Drugs and Therapeutics • February 8, 2021; (Issue 1617)
The FDA has approved osilodrostat (Isturisa –
Recordati), a cortisol synthesis inhibitor, for oral
treatment of adults with Cushing's disease when
surgical resection of the pituitary adenoma is not...
The FDA has approved osilodrostat (Isturisa –
Recordati), a cortisol synthesis inhibitor, for oral
treatment of adults with Cushing's disease when
surgical resection of the pituitary adenoma is not an
option or has not been curative. Osilodrostat is the
first cortisol synthesis inhibitor to be approved in
the US for this indication. Other oral steroidogenesis
inhibitors such as ketoconazole and metyrapone have
been used off-label for this indication for many years.
Mifepristone (Mifeprex) Label Changes
The Medical Letter on Drugs and Therapeutics • April 25, 2016; (Issue 1493)
The FDA has approved several significant changes in
the labeling of mifepristone (Mifeprex – Danco), an oral
antiprogestin that has been used in the US for more than
15 years for termination of...
The FDA has approved several significant changes in
the labeling of mifepristone (Mifeprex – Danco), an oral
antiprogestin that has been used in the US for more than
15 years for termination of intrauterine pregnancy. It
has generally been used with the prostaglandin analog
misoprostol (Cytotec, and generics).